Search Within

Solid Tumor Oncology Division

Formats
  1. Journal Article (10875)
  2. Meeting Abstract (9475)
  3. Review (551)
  4. Book Section (417)
  5. Editorial (334)
  6. Guidelines (157)
  7. Correspondence (116)
  8. Conference Paper (106)
  9. Research Letter (60)
  10. Miscellaneous (54)
  11. Book Whole (27)
Groups
  1. Department of Medicine (22150)
  2. GSK Faculty (5906)
  3. Genitourinary Oncology Service (5635)
  4. Survivorship Research (5212)
  5. Gastrointestinal Oncology Service (4672)
  6. Breast Medicine Service (4131)

More Groups

People
  1. Robert Motzer (1247)
  2. Howard Scher (1130)
  3. Clifford Hudis (905)
  4. Jedd Wolchok (905)
  5. Mark Kris (870)
  6. Leonard Saltz (791)

More People

Years
  1. 2025 (551)
  2. 2024 (1386)
  3. 2023 (1381)
  4. 2022 (1573)
  5. 2021 (1517)
  6. 2020 (1536)

More Years

Publications
  1. Journal of Clinical Oncology (5264)
  2. Annals of Oncology (1295)
  3. Cancer Research (1012)
  4. Clinical Cancer Research (772)
  5. Journal of Thoracic Oncology (531)
  6. Gynecologic Oncology (441)

More Publications

Publishers
  1. American Society of Clinical Oncology (5555)
  2. Elsevier Inc. (2654)
  3. American Association for Cancer Research (2322)
  4. Oxford University Press (1812)
  5. Nature Publishing Group (1030)
  6. Springer (979)

More Publishers

Results (22172)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Avelumab in metastatic Merkel cell carcinoma (mMCC): Conditional survival and long-term safety in patients treated for ≥1 or ≥2 years in JAVELIN Merkel 200
    Meeting Abstract

    Lebbe, C.; Nghiem, P.; Bhatia, S.; Mortier, L.; Brohl, A. S.; Jacob, N.; Tyroller, K.; Hoffman, J.; D'Angelo, S. P.
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Efficacy of LNS8801 in melanoma patients with prior immune-related adverse events from immune-checkpoint inhibitors
    Meeting Abstract

    Cohen, J. V.; Garyantes, T. K.; Muller, C.; Natale, C. A.; Orloff, M.; Patel, S.; Rodon, J.; Shoushtari, A. N.
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Longitudinal biomarker analysis and outcomes for patients (pts) treated with neoadjuvant nivolumab (nivo) and relatlimab (rela) in surgically resectable melanoma
    Meeting Abstract

    Burton, E.; Wani, K.; Milton, D.; Lazcano, R.; Tetzlaff, M.; Ross, M. I.; Postow, M. A.; Glitza, I. C.; Wong, M. K. K.; Patel, S.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Updated safety and efficacy from the phase I study of givastomig, a novel claudin 18.2/4-1BB bispecific antibody, in claudin 18.2 positive advanced gastroesophageal carcinoma (GEC)
    Meeting Abstract

    Klempner, S. J.; Shen, L.; Liu, D.; Dayyani, F.; Kratz, J.; Pan, H.; Liang, X.; Wang, Z.; Kim, S.; Deng, Y.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Five-year overall survival (OS) and OS by tumour response measures from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma (uHCC)
    Meeting Abstract

    Rimassa, L.; Chan, S. L.; Sangro, B.; Lau, G.; Kudo, M.; Breder, V.; Varela, M.; Crysler, O.; Bouattour, M.; Dao, V. T.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • First-in-human (FIH) phase I data of HST-1011, an oral CBL-B inhibitor, in patients with advanced solid tumors
    Meeting Abstract

    Sanborn, R. E.; Patel, M. R.; Rodon, J.; Thein, K. Z.; Friedman, C.; Levitz, D.; Ngirailemesang, I.; Goodman, A.; Agarwal, P.; Friedman, E.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Neoadjuvant cemiplimab with platinum-doublet chemotherapy and cetuximab to de-escalate surgery and omit adjuvant radiation in locoregionally advanced head & neck squamous cell carcinoma (HNSCC)
    Meeting Abstract

    Dunn, L.; Cracchiolo, J.; Ho, A. L.; Sherman, E. J.; Ganly, I.; Ghossein, R.; Cohen, M.; Wong, W.; Desilets, A.; Michel, L.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Phase II trial of ozuriftamab vedotin (BA3021), a conditionally active biologic (CAB)-ROR2-ADC, in patients with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN)
    Meeting Abstract

    Wong, W.; Adkins, D. R.; Misleh, J. G.; Lorch, J.; Grewal, J. S.; Russell, J.; Cetnar, J.; Ho, A. L.; Chen, K.; Aysola, K.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Phase II multicenter, randomized, double-blind, placebo-controlled study evaluating the efficacy of HB-200 in patients with detectable TTMV-HPV DNA after definitive treatment for HPV16 + HNSCC
    Meeting Abstract

    Ho, A. L.; Riaz, N.; Pfister, D.; Wong, R.; Lee, N.; Sherman, E. J.; Haque, S.; Ostrovnaya, I.; Wong, W.
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Safety and tolerability of durvalumab (D) + carboplatin/paclitaxel (CP) + bevacizumab (B) followed by D, B + olaparib (O) maintenance (mtx) in patients (pts) with newly diagnosed advanced ovarian cancer (AOC) without a tumour BRCA1/BRCA2 mutation (non-tBRCAm) in the phase III DUO-O trial
    Meeting Abstract

    Aghajanian, C.; Schmalfeldt, B.; Okamoto, A.; Reuss, A.; Kim, J. W.; Marquina Ospina, G.; Ayhan, A.; Salutari, V.; Lebreton, C.; Labudovic, D.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save